The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Open accessAbstract
Endocannabinoids are released following brain injury and may protect against excitotoxic damage during the acute stage of injury. Brain injury also activates microglia in a secondary inflammatory phase of more widespread damage. Most drugs targeting the acute stage are not effective if administered more than 6 hours after injury. Therefore, drugs targeting microglia later in the neurodegenerative cascade are desirable. We have found that cannabinoid CB2 receptors are up-regulated during the activation of microglia following brain injury. Specifically, CB2-positive cells appear in the rat brain following both hypoxia-ischemia (HI) and middle cerebral artery occlusion (MCAO). This may regulate post-injury microglial activation and inflammatory functions. In this paper we review in vivo and in vitro studies of CB2 receptors in microglia, including our results on CB2 expression post-injury. Taken together, studies show that CB2 is up-regulated during a process in which microglia become primed to proliferate, and then become fully reactive. In addition, CB2 activation appears to prevent or decrease microglial activation. In a rodent model of Alzheimer's disease microglial activation was completely prevented by administration of a selective CB2 agonist. The presence of CB2 receptors in microglia in the human Alzheimer's diseased brain suggests that CB2 may provide a novel target for a range of neuropathologies. We conclude that the administration of CB2 agonists and antagonists may differentially alter microglia-dependent neuroinflammation. CB2 specific compounds have considerable therapeutic appeal over CB1 compounds, as the exclusive expression of CB2 on immune cells within the brain provides a highly specialised target, without the psychoactivity that plagues CB1 directed therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“[45], characterising and cloning the CB2 receptor, was accompanied by the report that no CB2 mRNA was detected in the brain.”
BackgroundThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 3×
“2-arachidonoyl-glycerol (2-AG), was discovered later, and *Address correspondence to this author at Department of Pharmacology & Toxicology, University of Otago, PO Box 913, Dunedin, New Zealand; Email: +64 3 479 4174; Fax: +64 3 479 9140; E-mail: john.ashton@stonebow.otago.ac.nz in recent years, three more endocannab…”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 1×
“First, endocannabinoid activation of pre-synaptic CB1 receptors is known to reduce neurotransmitter release and, hence, excitotoxicity in postsynaptic neurons [36].”
BackgroundFelder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 869
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 785
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Evidence for stroke-induced neurogenesis in the human brain
Jin, K., Wang, X., Xie, L., Mao, X. O., Zhu, W., Wang, Y., Shen, J., Mao, Y., Banwait, S., & Greenberg, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603512103 · Cited by 628
Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain
ONAIVI, E. S., ISHIGURO, H., GONG, J., PATEL, S., PERCHUK, A., MEOZZI, P. A., MYERS, L., MORA, Z., TAGLIAFERRO, P., GARDNER, E., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.052 · Cited by 543
Peripheral cannabinoid receptor, CB2, regulates bone mass
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504187103 · Cited by 536
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 472
Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445 · cited 3×
“[15] used organotypic hippocampal slice cultures (OHSCs) to investigate the neurotoxic effects of BV-2 microglia.”
BackgroundMethodInfluentialMicroglial phenotype: is the commitment reversible?
Schwartz, M., Butovsky, O., Brück, W., & Hanisch, U.-K. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2005.12.005 · Cited by 434
Hevner, R. F., Hodge, R. D., Daza, R. A. M., & Englund, C. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.03.004 · Cited by 410
Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., & Leon, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 377
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 377
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606646200 · Cited by 363
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Carlisle, S. J., Marciano-Cabral, F., Staab, A., Ludwick, C., & Cabral, G. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00147-3 · Cited by 344
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00716.x · Cited by 315
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S., & Nagarkatti, M. (2002) · Blood · doi:10.1182/blood-2002-01-0098 · Cited by 288
Defective Adult Neurogenesis in CB1 Cannabinoid Receptor Knockout Mice
Jin, K., Xie, L., Kim, S. H., Parmentier-Batteur, S., Sun, Y., Mao, X. O., Childs, J., & Greenberg, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.2.204 · Cited by 273
The significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
Puffenbarger, R. A., Boothe, A. C., & Cabral, G. A. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<58::aid-glia6>3.0.co;2-w · Cited by 248
Klegeris, A., Bissonnette, C. J., & McGeer, P. L. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705304 · Cited by 246
Cannabinoid receptors in microglia of the central nervous system: immune functional relevance
Cabral, G. A., & Marciano-Cabral, F. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405216 · Cited by 240
Franklin, A., Parmentier-Batteur, S., Walter, L., Greenberg, D. A., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07767.2003 · Cited by 231
Panikashvili, D., Shein, N. A., Mechoulam, R., Trembovler, V., Kohen, R., Alexandrovich, A., & Shohami, E. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.004 · Cited by 230
Waksman, Y., Olson, J. M., Carlisle, S. J., & Cabral, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38093-0 · Cited by 222
Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study
Ashton, J. C., Friberg, D., Darlington, C. L., & Smith, P. F. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.038 · Cited by 207
Self-citationConti, S., Costa, B., Colleoni, M., Parolaro, D., & Giagnoni, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704466 · Cited by 190
McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M., & Nagarkatti, P. S. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033506 · Cited by 143
Ashton, J. C., Rahman, R. M. A., Nair, S. M., Sutherland, B. A., Glass, M., & Appleton, I. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.10.053 · Cited by 142
Self-citationEffects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice
Berdyshev, E. V., Boichot, E., Corbel, M., Germain, N., & Lagente, V. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00324-5 · Cited by 134
Protective autoimmunity against the enemy within: fighting glutamate toxicity
Schwartz, M. H., Shaked, I., Fisher, J., Mizrahi, T., & Schori, H. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00126-7 · Cited by 133
Fernández‐López, D., Martínez-Orgado, J. A., Núñez, E., Romero, J., Lorenzo, P. L., Moro, M. Á., & Lizasoaín, I. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000228839.00122.6c · Cited by 115
Franklin, A., & Stella, N. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02074-0 · Cited by 111
Ortega‐Gutiérrez, S., Molina‐Holgado, E., & Guaza, C. (2005) · Glia · doi:10.1002/glia.20229 · Cited by 109
Bone Cancer Pain: From Mechanism to Model to Therapy
Honoré, P., & Mantyh, P. W. (2000) · Pain Medicine · doi:10.1046/j.1526-4637.2000.00047.x · Cited by 98
Armentero, M., Fancellu, R., Nappi, G., Bramanti, P., & Blandini, F. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.09.010 · Cited by 97
Endogenous Cannabinoid Receptor Ligand Induces the Migration of Human Natural Killer Cells
Kishimoto, S. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi021 · Cited by 96
Ryu, J. K., Choi, H. B., & McLarnon, J. G. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.043 · Cited by 78
Formation of B and T cell subsets require the cannabinoid receptor CB2
Ziring, D., Wei, B., Velazquez, P., Schrage, M., Buckley, N. E., & Braun, J. (2006) · Immunogenetics · doi:10.1007/s00251-006-0138-x · Cited by 75
Mukhopadhyay, S., Das, S., Williams, E. A., Moore, D., Jones, J. D., Zahm, D. S., Ndengele, M. M., Lechner, A. J., & Howlett, A. C. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.08.002 · Cited by 68
Rosi, S., Pert, C. B., Ruff, M. R., McGann-Gramling, K. R., & Wenk, G. L. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.029 · Cited by 65
Stimulus-specific inhibition of intracellular adhesion molecule-1 gene expression by TGF-beta
Shrikant, P., Lee, S. J., Kalvakolanu, I., Ransohoff, R. M., & Benveniste, E. N. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.892 · Cited by 63
AM630 is an inverse agonist at the human cannabinoid CB1 receptor
Landsman, R. S., Makriyannis, A., Deng, H., Consroe, P. F., Roeske, W. R., & Yamamura, H. I. (1998) · Life Sciences · doi:10.1016/s0024-3205(97)01187-9 · Cited by 61
Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils
Bar-Joseph, A., Berkovitch, Y., Adamchik, J., & Biegon, A. R. (1994) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815406 · Cited by 61
Endocannabinoids and the gastrointestinal tract.
Massa, F., & Monory, K. (2006) · PubMed · Cited by 58
Chesterfield, A. K., Kidd, S. R., Moore, S. A., Schaus, J. M., Liu, B., Nomikos, G. G., & Felder, C. C. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9072-6 · Cited by 55
Role of cannabinoid receptors in inhibiting macrophage costimulatory activity
Chuchawankul, S., Shima, M., Buckley, N. E., Hartmann, C. B., & McCoy, K. L. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2003.12.011 · Cited by 54
Stefano, G. B., Esch, T., Cadet, P., Zhu, W. M., Mantione, K. J., & Benson, H. (2003) · PubMed · Cited by 36
CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis
Wasmuth, H. E., & Trautwein, C. (2007) · Hepatology · doi:10.1002/hep.21527 · Cited by 33
Smith, P. F. (2004) · PubMed · Cited by 19
Current and future pharmacological interventions for the acute treatment of ischaemic stroke
Rahman, R. M. A., Nair, S. M., & Appleton, I. (2005) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2005.04.003 · Cited by 8
Cited by
Pathological and protective roles of glia in chronic pain
Milligan, E. D., & Watkins, L. R. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2533 · Cited by 1,399
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Di Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279
Metadata
- Authors
- Ashton, J., & Glass, M.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-06-01
- Volume
- 5
- Issue
- 2
- Pages
- 73-80
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2015264989
- Cited by
- 331
- References
- 58
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.